| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/30/2006 | WO2005105769A3 Mycophenolate mofetil impurity |
| 03/30/2006 | WO2005105049A8 Orally disintegrating tablets and methods of manufacture |
| 03/30/2006 | WO2005103710A3 Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 1 (crhr1) |
| 03/30/2006 | WO2005102346A3 Use of c-kit inhibitors for treating fibrosis |
| 03/30/2006 | WO2005102326A3 Use of c-kit inhibitors for treating renal diseases |
| 03/30/2006 | WO2005102316A3 Use of coumarin derivatives |
| 03/30/2006 | WO2005102275A3 Galantamine salts, method of producing it and nasal composition thereof |
| 03/30/2006 | WO2005102274A3 Method of stabilizing disordered cefovecin sodium salt |
| 03/30/2006 | WO2005097192A3 Active substance combination of a carbinol compound and an opioid |
| 03/30/2006 | WO2005097107A3 Diphenyl - indol-2-on compounds and their use in the treatment of cancer |
| 03/30/2006 | WO2005094251A3 M3muscarinic acetylcholine receptor antagonists |
| 03/30/2006 | WO2005094210A3 Multi-action anthelmintic formulations |
| 03/30/2006 | WO2005090372A3 Platinum carboxylate anticancer compounds |
| 03/30/2006 | WO2005087216A3 Treatment of anaemic conditions by inhibition of erythrocyte apoptosis |
| 03/30/2006 | WO2005082331A3 Extended release tablets of clarithromycin |
| 03/30/2006 | WO2005081960A3 Inhibitors of protein tyrosine phosphatase 1b |
| 03/30/2006 | WO2005074901A3 New effector conjugates, process for their production and their pharmaceutical use |
| 03/30/2006 | WO2005070398A3 Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents |
| 03/30/2006 | WO2005067973A3 Combination of crf antagonists and 5-ht 1b receptor antagonists |
| 03/30/2006 | WO2005062847A3 Compounds, compositions and methods |
| 03/30/2006 | WO2005060940A3 Method for the production of a solid, orally applicable pharmaceutical composition |
| 03/30/2006 | WO2005058367A3 Pegylated small molecules |
| 03/30/2006 | WO2005055955A3 DOSING METHODS FOR ß-D-2’,3’-DIDEOXY-2’,3’-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY |
| 03/30/2006 | WO2005049024A3 Solid pharmaceutical preparation form |
| 03/30/2006 | WO2005048993A3 Minimization of drug oxidation in drug irradiated excipients formulations |
| 03/30/2006 | WO2005048946A3 Treatment for burn victims and animal carcasses |
| 03/30/2006 | WO2005048942A3 Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent |
| 03/30/2006 | WO2005047321A3 Polynucleotides for inhibition of polypeptide expression and methods of use |
| 03/30/2006 | WO2005044246A3 Controlled release analgesic suspensions |
| 03/30/2006 | WO2005044243A3 Transdermal analgesic systems having reduced abuse potential |
| 03/30/2006 | WO2005040169A3 Fused heterocyclic compounds as serotonin receptor modulators |
| 03/30/2006 | WO2005037825A3 Protein kinase inhibitors |
| 03/30/2006 | WO2005025510A3 Cox-2 selective inhibitor with extended duration |
| 03/30/2006 | WO2005019211A3 Biaryl heterocyclic compounds and methods of making and using the same |
| 03/30/2006 | WO2004113330A8 Immunosuppressant compounds and compositions |
| 03/30/2006 | WO2004096199A3 Regulation of guanine nucleotide exchange factor |
| 03/30/2006 | WO2004093853A3 Taurine bromamine for inhibiting pathogenic bacteria and fungi growth as well as in a microbicidal composition |
| 03/30/2006 | WO2004092346A3 Small molecule inhibition of a pdz-domain interaction |
| 03/30/2006 | WO2004089298A3 5-htp composition |
| 03/30/2006 | WO2004087893A9 Compositions comprising lactobacillus plantarum strains in combination with tannin and new lactobacillus plantarum strains |
| 03/30/2006 | WO2004071417A3 Inhibitors of candida albicans |
| 03/30/2006 | WO2004070012A3 Cell-killing molecules and methods of use thereof |
| 03/30/2006 | WO2004065932A3 Methods of identifying modulators of cellular glycosylation using gtrap3-18 |
| 03/30/2006 | WO2004053071A3 Method for discovering neurogenic agents |
| 03/30/2006 | US20060069410 Method and system for terminating an atrial arrhythmia |
| 03/30/2006 | US20060069344 Device for transdermal electrotransport delivery of fentanyl and sufentanil |
| 03/30/2006 | US20060069271 Alpha crystalline form of strontium ranelate |
| 03/30/2006 | US20060069265 Reacting cysteine (or a salt or an ester) and an aryl carboxylic acid to form a thiazoline ring; stereospecifically alkylating the thiazoline ring, and hydrolyzing the thiazoline ring to obtain a 2-alkylcysteine; chelation |
| 03/30/2006 | US20060069264 Aza hydroxylated ethyl amine compounds |
| 03/30/2006 | US20060069259 N-(trans-2,3-di-n-amyl-2-butenoic acid amide)-L-phenylglycinamide;treating hypertension, deficiency of magnesium ion bound to the plasma membranes of their somatic cells; sodium-sensitive essential hypertension and Type 2 insulin-resistant diabetes mellitus |
| 03/30/2006 | US20060069256 Ophthalmic compositions for treating ocular hypertension |
| 03/30/2006 | US20060069254 Method for the production of alkoxycarbonylamino triazines |
| 03/30/2006 | US20060069246 Tumor necrosis factor receptor related proteins Tango-63d and Tango-63e |
| 03/30/2006 | US20060069242 Neurotrophic factor receptor |
| 03/30/2006 | US20060069167 1-chloro-2,4-dinitrobenzene gel compositions and methods for using the same |
| 03/30/2006 | US20060069166 Laser treatment of cutaneous vascular lesions |
| 03/30/2006 | US20060069165 Treating morning hypertension by lowering morning blood pressure levels with propranolol |
| 03/30/2006 | US20060069164 Reacting N-(3-leaving group-2-propenyl)-N-methyl-1-naphthalenemethanamine with tert-butylacetylene in presence of platinum catalyst; chemical intermediates |
| 03/30/2006 | US20060069163 Method for treating Alzheimer's disease |
| 03/30/2006 | US20060069162 Transparent eye drops containing latanoprost |
| 03/30/2006 | US20060069161 mixtures of fibrates selected from bezafibrate, binifibrate, ciprofibrate, clinofibrate, clofibrate, etofibrate, fenofibrate or gemfibrozil, and diflunisal, a diflunisal analog, cinnamic acid or a cinnamic acid analog, used for treating diabetes, obesity and non-insulin dependent diabetes |
| 03/30/2006 | US20060069160 Solvent extract prepared by mixing methionine with water, adding an aqueous hypochlorite solution and mixing at 0 degrees C. to ambient temperature, adding a water-immiscible organic solvent and mixing, and separating; economic, easy to manufacture, effective, and has no significant side effects |
| 03/30/2006 | US20060069159 Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation |
| 03/30/2006 | US20060069158 Lipoxin compounds and their use in treating cell proliferative disorders |
| 03/30/2006 | US20060069157 Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as Huntington's disease, by sodium butyrate chemotherapy |
| 03/30/2006 | US20060069156 Acylated aminopropanediols and analogues and therapeutic uses thereof |
| 03/30/2006 | US20060069155 reducing the incidences and/or the severity by administering a phosphodiesterase 4 (PDE4) inhibitor. |
| 03/30/2006 | US20060069154 Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs |
| 03/30/2006 | US20060069153 Administering dithiocarbamate compound having the structural formula R1R2NCS2H for therapy of infection by an RNA virus which attacks the respiratory tract and causes disease selected from picornavirus, ortho-myxovirus, rhinovirus, enterovirus, coxsackie virus, aphthovirus, or paramyxovirus |
| 03/30/2006 | US20060069152 Crystalline mycophenolate sodium |
| 03/30/2006 | US20060069151 Novel use of lycopene |
| 03/30/2006 | US20060069150 Processes for preparation of crystalline mycophenolate sodium |
| 03/30/2006 | US20060069149 Thiadibenzoazulene derivatives for the treatment of inflammatory diseases |
| 03/30/2006 | US20060069148 Prostaglandins for prostaglandin mediated diseases such as antihistamines |
| 03/30/2006 | US20060069147 hydrolase enzyme antagonists such as N-{(6S,9R,11R)-2-[5-4-fluoroophenyl)-1-methyl-1H-pyrazol-3-yl]-5,6,7,8,9,10-hexahydro-6,9-methanobenzo[a][8]annulen-11-yl}-N'-(2,2,2-trifiuoroethyl)sulfamide that inhibit processing of amyloid precursor protein, useful in treating or preventing Alzheimer's disease |
| 03/30/2006 | US20060069146 Cardiovascular disordders; antiarrhythmia agents; neurodegenerative diseases; antidepressants; bipolar disorders; irritable bowel disorders |
| 03/30/2006 | US20060069145 Tricycles, their manufacture and use as pharmaceutical agents |
| 03/30/2006 | US20060069144 Chronic pain, allodynia, muscle spasticity, diarrhea, neuropathic pain; compounds have no or only minimal cardiovascular and/or sedatory activity; minimal side effects; 4-Benzo[1,2,5]thiadiazol-4-ylmethyl-1,3-dihydro-imidazole-2-thione |
| 03/30/2006 | US20060069143 4-(Heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists |
| 03/30/2006 | US20060069142 Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same |
| 03/30/2006 | US20060069141 Trityl olmesartan medoxomil is reacted with an acid in a water miscible organic solvent, separating the precipitate of triphenyl carbinol from the solution of olmesartan medoxomil; solution of olmesartan medoxomil is treated with a base to obtain a precipitate of olmesartan medoxomil |
| 03/30/2006 | US20060069140 Pyrazolone compounds and thrombopoietin receptor activator |
| 03/30/2006 | US20060069139 4-Methyl-5-(-2-nitrooxy-ethyl)-2-(1-nitrooxy-ethyl)-thiazole for example; compound forms a naturally occurring metabolite when NO is released; treating cardiovascular diseases, inflammation, psychiatric and neurological diseases, respiratory diseases, urogenital disorders |
| 03/30/2006 | US20060069138 Thiazole-based nitric oxide donors having alkyl substuent(s) and uses thereof |
| 03/30/2006 | US20060069137 Novel process for ezetimibe intermediate |
| 03/30/2006 | US20060069136 Use of Epothilones in the treatment of bone metastasis |
| 03/30/2006 | US20060069135 Benzimidazole derivatives and their use for modulating the gaba-a receptor complex |
| 03/30/2006 | US20060069134 Process for producing optically active alpha-substituted cysteine or salt thereof, intermediate therefor, and process for producing the same |
| 03/30/2006 | US20060069133 Administering a composition consisting of 2-ethoxy-1-[[2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid, a prodrug thereof or a salt thereof, a PPAR gamma agonist-like substance; diabetes, obesity |
| 03/30/2006 | US20060069132 Azolecarboxamide herbicides |
| 03/30/2006 | US20060069131 Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives |
| 03/30/2006 | US20060069130 Novel crystals |
| 03/30/2006 | US20060069129 Chemokine receptor binding heterocyclic compounds |
| 03/30/2006 | US20060069128 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| 03/30/2006 | US20060069127 Such as R) N-{1-[1-(4-Ethoxy-phenyl)-4-phenyl-1H-imidazol-2-yl]-ethyl}-2-(4-fluoro-3-trifluoromethyl-phenyl)-N-pyridin-3-ylmethyl-acetamide, for therapy of inflammatory and immune disorders and disease such as multiple sclerosis, rheumatoid arthritis, psoriasis, and inflammatory bowel disease |
| 03/30/2006 | US20060069126 Pharmaceutically active isoindoline derivatives |
| 03/30/2006 | US20060069125 Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride |
| 03/30/2006 | US20060069124 Use of MDL-100,907 for treatment of allergic and eosinophil mediated diseases |
| 03/30/2006 | US20060069123 Substituted dipiperidine CCR2 antagonists |
| 03/30/2006 | US20060069122 storage stability; autoimmune diseases |